U.S., Drug Companies To Increase Production Of Experimental Ebola Drugs; Canada Ships Experimental Vaccine To Geneva, U.S.
News outlets report on various aspects of developing, testing, and distributing experimental vaccines and treatments for Ebola.
CNBC: Ebola vaccine: Why it’s taking so long to make one
“…Thomas Eric Duncan, the Liberian man who is undergoing treatment for Ebola and listed in serious condition in Dallas, won’t be getting the experimental drug ZMapp used on several international aid workers and medical staff, including at least two other Americans. That’s because the company that makes ZMapp, Mapp Biopharmaceutical, has run out of supplies. This just highlights how difficult it is to develop new medicines…” (Koba, 10/1).
New York Times: U.S. Will Increase Production of the Ebola Drug ZMapp, but May Not Meet Demand
“Federal officials are planning to sharply increase production of ZMapp, which is viewed by many experts as the most promising experimental drug for treating people infected with Ebola in West Africa…” (Pollack, 10/1).
Reuters: GlaxoSmithKline, NewLink working to bring Ebola vaccines online: WHO
“Both GlaxoSmithKline and NewLink Genetics are working to boost their capacity to make Ebola vaccines, with a goal of a ‘very significant increase in scale during the first half of 2015,’ the World Health Organization said on Wednesday…” (Nebehay, 10/1).
Reuters: Canada vaccine shipped to Geneva, U.S. hospitals as precaution
“Canada has shipped small amounts of its experimental vaccine for the Ebola virus to hospitals in Geneva and Atlanta, Georgia, for possible use by exposed health care workers, Canadian chief public health officer Greg Taylor said on Wednesday…” (Nickel, 10/1).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.